Theravance Biopharma, Inc. (TBPH) Stock Price & Analysis

Theravance Biopharma, Inc. (TBPH) rose 1.23% to USD 16.49 as of June 10, 2026 at 03:37 UTC, according to Nexqual real-time market data.

TBPH last closed at USD 16.29; the session ranged USD 16.35–16.54 on volume of 332,098 shares. Market capitalization is $850.11M, with a 52-week range of USD 10.42–21.03 (NGM). Source: Nexqual, June 10, 2026 at 03:37 UTC.

Key Statistics (as of June 10, 2026 at 03:37 UTC)

Technical Analysis (TBPH)

Nexqual's technical model rates TBPH "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:37 UTC.

Analyst Ratings (TBPH)

Wall Street analysts rate TBPH "Buy" based on 5 analysts, with a mean price target of USD 17.4 (range USD 15–21), per Nexqual as of June 10, 2026 at 03:37 UTC.

Earnings (TBPH)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:37 UTC.

Financials & Fundamentals (TBPH)

Source: Nexqual, June 10, 2026 at 03:37 UTC.

Financial Health Score (TBPH)

Nexqual rates Theravance Biopharma, Inc.'s overall financial health "Strong" across five dimensions, as of June 10, 2026 at 03:37 UTC.

Ownership (TBPH)

Source: Nexqual, June 10, 2026 at 03:37 UTC.

Leadership (TBPH)

Theravance Biopharma, Inc. is led by Rick E. Winningham (age 65), CEO & Director, per Nexqual as of June 10, 2026 at 03:37 UTC.

Major Backers & Investors (TBPH)

Notable institutional backers of Theravance Biopharma, Inc. include Madison Avenue Partners, LP, Weiss Asset Management Lp, Newtyn Management, Llc, according to Nexqual as of June 10, 2026 at 03:37 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 03:37 UTC.

From Theravance Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)

Key Strengths & Strategy (as disclosed to the SEC)

• Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities.
• Where it is necessary to share our proprietary information or data with outside parties, our policy is to make available only that information and data required to accomplish the desired purpose and only pursuant to a duty of confidentiality on the part of those parties. 13 Table of Contents ​ As of December 31, 2025, we owned a total of 119 issued US patents and 666 granted foreign patents, as well as additional pending US patent applications and foreign patent applications.
• Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development. ​ Fraud and Abuse Laws Our interactions and arrangements with customers and third-party payors are subject to applicable US federal and state fraud and abuse laws and equivalent third country laws.

Partnerships

• In addition, in January 2026, we received a $25.0 million milestone payment for the achievement of $250.0 million in US net sales in 2025. ​ 4 Table of Contents Sale of TRELEGY ® Royalties In June 2025, we sold our remaining royalty interest in the global net sales of TRELEGY to GSK plc for $225.0 million while retaining our right to receive up to $150.0 million in remaining potential milestone payments from Royalty Pharma Investments.
• In May 2023, we announced that the FDA granted Orphan Drug Designation status to ampreloxetine for the treatment of symptomatic nOH in patients with MSA.    In July 2022, Royalty Pharma Investments ("Royalty Pharma") agreed to invest up to $40.0 million to advance the development of ampreloxetine in MSA in exchange for unsecured low single-digit royalties.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:37 UTC. This page is informational and not investment advice.